Skip to content
Not evaluated by SAHPRA · Research & educational information only · Nothing on this site is for sale · Not medical advice · Consult a healthcare professional
Not evaluated by SAHPRA. Research & educational information only — nothing is for sale; not intended to diagnose, treat, cure or prevent any disease.
← Back to catalogue
Weight LossResearch vialGLP-1GIPWeight lossOnce weeklyDual agonist

Tirzepatide

Dual GLP-1 + GIP agonist — deeper weight loss with cleaner GI per kilo lost.

Format
Research vial
Strength / pack
30mg vial
Category
Weight Loss
Dual receptor actionActivates GLP-1 and GIP receptors simultaneously for amplified metabolic effect.
Up to 20.9% lossSURMOUNT-1 reported 20.9% mean weight loss at 15 mg over 72 weeks.
Insulin sensitisationGIP arm appears to amplify insulin response and improve glucose handling.
Better GI toleranceLower side-effect burden per unit of weight loss compared with single-receptor analogs.
Tirzepatide is a synthetic dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The added GIP arm appears to amplify insulin sensitisation and may reduce the gastrointestinal side-effect burden per unit of weight loss. Administered subcutaneously once weekly.
Publisher
Elegant Slimming · Mokopane, Limpopo, South Africa
Research library · nothing on this site is for sale.
Regulatory
This compound has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.